<DOC>
	<DOCNO>NCT01258101</DOCNO>
	<brief_summary>This randomize , parallel arm study evaluate efficacy safety Pegasys ( peginterferon alfa-2a ) combination 2 different dos ribavirin patient chronic hepatitis C , genotype 2 3 . Patients randomize 4 treatment group receive Pegasys ( 180 mcg subcutaneously weekly ) either 16 24 week one two dos ribavirin ( 400 mg 800 mg orally daily ) . The anticipated time study treatment 16 24 week 24-week follow-up .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ) Plus Ribavirin Patients With Chronic Hepatitis C ( CHC ) , Genotype 2 3</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , 1865 year age Chronic hepatitis C , genotype 2 3 Positive HCV RNA level serum screening ( COBAS AMPLICOR MONITOR HCV test ) Abdominal sonography within 3 month prior study start Previous interferon and/or pegylated interferon ribavirin therapy Liver cirrhosis , class B C ( ChildPugh ) Systemic antineoplastic immunomodulatory treatment &lt; =6 month study drug History evidence medical condition associate chronic liver disease chronic hepatitis C Decompensated liver disease Positive HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>